Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
OSASD
MCID: PTN001
MIFTS: 62

Patent Foramen Ovale (OSASD)

Categories: Blood diseases, Cardiovascular diseases, Fetal diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Patent Foramen Ovale

About this section

MalaCards integrated aliases for Patent Foramen Ovale:

Name: Patent Foramen Ovale 12 29 6 15
Atrial Septal Defect, Ostium Secundum Type 58 6
Foramen Ovale, Patent 44 71
Foramen Ovale Patent 12 54
Defect, Patent or Persistent, Ostium Secundum 12
Ostium Secundum Type Atrial Septal Defect 12
Atrial Septal Defect Within Oval Fossa 12
Ostium Secundum Atrial Septal Defect 20
Persistent Ostium Secundum 12
Asd, Ostium Secundum Type 58
Asd Ostium Secundum Type 20
Ostium Secundum Asd 20
Osasd 20

Classifications:

MalaCards categories:
Global: Rare diseases Fetal diseases
Anatomical: Cardiovascular diseases Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare cardiac malformations
Developmental anomalies during embryogenesis


Sources

Summaries for Patent Foramen Ovale

About this section
GARD : 20 An ostium secundum atrial septal defect is a type of congenital heart defect called an atrial septal defect (ASD). An ASD is a hole in the wall (septum) between the two upper chambers of the heart (the atria). ASDs can be classified by location. An ostium secundum ASD is a hole in the center of the atrial septum. Normally, the right side of the heart pumps oxygen-poor blood to the lungs, while the left side pumps oxygen-rich blood to the body. An ASD allows blood from both sides to mix, causing the heart to work less efficiently. A small hole may not cause any symptoms or problems. A larger hole can eventually cause symptoms such as shortness of breath, respiratory infections, fainting, irregular heart rhythms or fatigue after mild activity. Larger ASDs can also ultimately lead to pulmonary artery hypertension, right ventricular hypertrophy (enlargement); SVT, or heart failure. Most cases of ASD are not inherited and occur by chance. Some cases appear to have autosomal dominant inheritance. Treatment may not be needed for small ASDs, which often close on their own. Larger ASDs are typically closed during childhood with open heart surgery or by cardiac catheterization.

MalaCards based summary : Patent Foramen Ovale, also known as atrial septal defect, ostium secundum type, is related to tricuspid atresia and hypoplastic left heart syndrome. An important gene associated with Patent Foramen Ovale is TBX5 (T-Box Transcription Factor 5), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Cardiac conduction. The drugs Warfarin and Coagulants have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and endothelial, and related phenotypes are left-to-right shunt and fatigue

Wikipedia : 74 Atrial septal defect (ASD) is a congenital heart defect in which blood flows between the atria (upper... more...

Sources

Related Diseases for Patent Foramen Ovale

About this section

Diseases related to Patent Foramen Ovale via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 430)
# Related Disease Score Top Affiliating Genes
1 tricuspid atresia 32.8 TBX5 TBX20 NKX2-5 GATA6 GATA4
2 hypoplastic left heart syndrome 32.8 TBX5 TBX20 NKX2-5 MYH6 GATA6 GATA4
3 migraine with or without aura 1 32.7 TAB2 MTHFR F2 APOH
4 pulmonary embolism 32.7 SERPINC1 MTHFR F5 F2 APOH
5 stroke, ischemic 32.7 SERPINC1 MTHFR F5 F2 APOH
6 heart septal defect 32.4 TBX5 TBX20 PTPN11 NKX2-5 MYH6 GATA6
7 atrial heart septal defect 32.3 TLL1 TBX5 TBX20 SERPINC1 PTPN11 NKX2-5
8 migraine with aura 32.2 MTHFR F5 F2
9 thrombosis 32.1 SERPINC1 MTHFR F5 F2 APOH
10 intracranial embolism 32.1 SERPINC1 F2
11 thrombophilia 32.0 SERPINC1 MTHFR F5 F2 APOH
12 thrombophilia due to thrombin defect 32.0 SERPINC1 MTHFR F5 F2 APOH
13 endocarditis 32.0 SERPINC1 F2 APOH
14 branch retinal artery occlusion 31.8 SERPINC1 MTHFR F2 APOH
15 retinal artery occlusion 31.8 SERPINC1 MTHFR F5 F2 APOH
16 cerebrovascular disease 31.8 MTHFR F5 F2 APOH
17 myocardial infarction 31.8 SERPINC1 MYH6 MTHFR GATA4 F5 F2
18 interatrial communication 31.8 TLL1 TBX5 TBX20 NKX2-5 MYH6 GATA6
19 patent ductus arteriosus 1 31.7 TBX5 TBX20 PTPN11 NSD1 NKX2-5 MYH6
20 ventricular septal defect 31.6 TBX5 TBX20 NKX2-5 GATA6 GATA4 CITED2
21 varicose veins 31.6 SERPINC1 MTHFR F5 F2
22 antiphospholipid syndrome 31.6 SERPINC1 MTHFR F5 F2 APOH
23 pulmonary valve stenosis 31.6 TBX5 TBX20 PTPN11 NKX2-5 GATA4
24 vascular disease 31.6 SERPINC1 MTHFR F5 F2 APOH
25 heart disease 31.5 TBX5 TBX20 SERPINC1 PTPN11 NSD1 NKX2-5
26 protein s deficiency 31.5 SERPINC1 MTHFR F5 F2 APOH
27 amaurosis fugax 31.5 MTHFR F5
28 may-thurner syndrome 31.5 F5 APOH
29 homocysteinemia 31.5 SERPINC1 MTHFR F5 F2 APOH
30 mitral valve insufficiency 31.4 TBX5 MYH6 F2
31 dextro-looped transposition of the great arteries 31.4 TBX5 NKX2-5 GATA4
32 atrioventricular block 31.4 TBX5 NKX2-5 GATA4
33 central retinal artery occlusion 31.4 SERPINC1 MTHFR F2
34 thrombophilia due to activated protein c resistance 31.4 SERPINC1 MTHFR F5 F2 APOH
35 splenic infarction 31.4 SERPINC1 F2 APOH
36 venous insufficiency 31.4 MTHFR F5 F2
37 tetralogy of fallot 31.4 TBX5 TBX20 PTPN11 NKX2-5 MYH6 MTHFR
38 peripheral vascular disease 31.3 SERPINC1 MTHFR F5 F2
39 aortic valve disease 2 31.3 TBX5 NKX2-5 MYH6 GATA4
40 spinal cord infarction 31.2 SERPINC1 MTHFR F5 F2 APOH
41 protein c deficiency 31.2 SERPINC1 MTHFR F5 F2 APOH
42 heart valve disease 31.2 NKX2-5 MYH6 F2 APOH
43 pre-eclampsia 31.2 SERPINC1 NSD1 MTHFR F5 F2 APOH
44 ebstein anomaly 31.2 TBX5 TBX20 NKX2-5 MYH6 GATA4 ACTC1
45 essential thrombocythemia 31.1 SERPINC1 PTPN11 MTHFR F2
46 sudden sensorineural hearing loss 31.1 MTHFR F5 F2
47 hypertrophic cardiomyopathy 31.0 PTPN11 NKX2-5 MYH6 GATA6 GATA4 ACTC1
48 homocystinuria 31.0 SERPINC1 MTHFR F5
49 catastrophic antiphospholipid syndrome 31.0 MTHFR F5 APOH
50 eclampsia 31.0 SERPINC1 MTHFR F2

Graphical network of the top 20 diseases related to Patent Foramen Ovale:



Diseases related to Patent Foramen Ovale
Sources

Symptoms & Phenotypes for Patent Foramen Ovale

About this section

Human phenotypes related to Patent Foramen Ovale:

58 31 (show all 37)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 left-to-right shunt 58 31 hallmark (90%) Very frequent (99-80%) HP:0012382
2 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
3 exertional dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002875
4 palpitations 58 31 frequent (33%) Frequent (79-30%) HP:0001962
5 exercise intolerance 58 31 frequent (33%) Frequent (79-30%) HP:0003546
6 right atrial enlargement 58 31 frequent (33%) Frequent (79-30%) HP:0030718
7 systolic heart murmur 58 31 frequent (33%) Frequent (79-30%) HP:0031664
8 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
9 mitral regurgitation 58 31 occasional (7.5%) Occasional (29-5%) HP:0001653
10 bundle branch block 58 31 occasional (7.5%) Occasional (29-5%) HP:0011710
11 abnormal mitral valve morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0001633
12 pulmonary arterial hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0002092
13 atrial fibrillation 58 31 occasional (7.5%) Occasional (29-5%) HP:0005110
14 tricuspid regurgitation 58 31 occasional (7.5%) Occasional (29-5%) HP:0005180
15 pedal edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0010741
16 first degree atrioventricular block 58 31 occasional (7.5%) Occasional (29-5%) HP:0011705
17 breathing dysregulation 58 31 occasional (7.5%) Occasional (29-5%) HP:0005957
18 right ventricular dilatation 58 31 occasional (7.5%) Occasional (29-5%) HP:0005133
19 orthopnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0012764
20 supraventricular tachycardia 58 31 occasional (7.5%) Occasional (29-5%) HP:0004755
21 atrial flutter 58 31 occasional (7.5%) Occasional (29-5%) HP:0004749
22 st segment depression 58 31 occasional (7.5%) Occasional (29-5%) HP:0012250
23 abnormal left ventricular function 31 occasional (7.5%) HP:0005162
24 transient ischemic attack 58 31 very rare (1%) Very rare (<4-1%) HP:0002326
25 syncope 58 31 very rare (1%) Very rare (<4-1%) HP:0001279
26 pneumonia 58 31 very rare (1%) Very rare (<4-1%) HP:0002090
27 cyanosis 58 31 very rare (1%) Very rare (<4-1%) HP:0000961
28 recurrent bacterial infections 58 31 very rare (1%) Very rare (<4-1%) HP:0002718
29 increased pulmonary vascular resistance 58 31 very rare (1%) Very rare (<4-1%) HP:0005317
30 right ventricular failure 58 31 very rare (1%) Very rare (<4-1%) HP:0001708
31 airway obstruction 31 very rare (1%) HP:0006536
32 supraventricular arrhythmia 58 Occasional (29-5%)
33 dyspnea 58 Occasional (29-5%)
34 arrhythmia 58 Occasional (29-5%)
35 stroke 58 Very rare (<4-1%)
36 obstructive lung disease 58 Very rare (<4-1%)
37 left ventricular dysfunction 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Patent Foramen Ovale:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.32 ACTC1 CITED2 F2 F5 GATA4 GATA6
2 growth/size/body region MP:0005378 10.31 ACTC1 CITED2 F2 F5 FGF14 GATA4
3 homeostasis/metabolism MP:0005376 10.31 ACTC1 APOH CITED2 F2 F5 GATA4
4 embryo MP:0005380 10.27 ACTC1 CITED2 F2 F5 GATA4 GATA6
5 mortality/aging MP:0010768 10.19 ACTC1 APOH CITED2 F2 F5 GATA4
6 liver/biliary system MP:0005370 9.97 F5 GATA4 GATA6 MTHFR MYH6 PTPN11
7 muscle MP:0005369 9.93 ACTC1 F2 FGF14 GATA4 GATA6 MYH6
8 limbs/digits/tail MP:0005371 9.91 CITED2 GATA4 GATA6 MTHFR PTPN11 TBX5
9 nervous system MP:0003631 9.7 ACTC1 CITED2 F2 F5 FGF14 GATA4
10 normal MP:0002873 9.28 ACTC1 CITED2 F2 GATA4 GATA6 NKX2-5
Sources

Drugs & Therapeutics for Patent Foramen Ovale

About this section

Drugs for Patent Foramen Ovale (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Warfarin Approved Phase 4 81-81-2 6691 54678486
2 Coagulants Phase 4
3
Dipyridamole Approved Phase 3 58-32-2 3108
4
Apixaban Approved Phase 3 503612-47-3 10182969
5
Rivaroxaban Approved Phase 3 366789-02-8
6
Dabigatran Investigational Phase 3 211914-51-1
7 Anti-Inflammatory Agents Phase 3
8 Analgesics, Non-Narcotic Phase 3
9 Fibrinolytic Agents Phase 3
10 Cyclooxygenase Inhibitors Phase 3
11 Anti-Inflammatory Agents, Non-Steroidal Phase 3
12 Analgesics Phase 3
13 Antirheumatic Agents Phase 3
14 Antipyretics Phase 3
15 Antithrombins Phase 3
16 Serine Proteinase Inhibitors Phase 3
17 HIV Protease Inhibitors Phase 3
18 Factor Xa Inhibitors Phase 3
19 Antithrombin III Phase 3
20
protease inhibitors Phase 3
21 Phosphodiesterase Inhibitors Phase 3
22 Vasodilator Agents Phase 3
23 Aspirin, Dipyridamole Drug Combination Phase 3
24 Antivitamins K Phase 3
25 Pharmaceutical Solutions Phase 3
26
Serine Investigational, Nutraceutical Phase 3 56-45-1 5951
27
Dalteparin Approved Phase 2 9005-49-6
28
Tinzaparin Approved Phase 2 9041-08-1, 9005-49-6 25244225
29 Anticonvulsants Phase 2
30 Heparin, Low-Molecular-Weight Phase 2
31 Antidepressive Agents Phase 2
32 Calcium, Dietary Phase 2
33
Calcium Nutraceutical Phase 2 7440-70-2 271
34
Aspirin Approved, Vet_approved 50-78-2 2244
35
Heparin Approved, Investigational 9005-49-6 772 9812414
36
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
37
tannic acid Approved 1401-55-4
38
Sodium citrate Approved, Investigational Early Phase 1 68-04-2
39
Clopidogrel Approved 120202-66-6, 113665-84-2 60606
40 Kava Approved, Investigational, Nutraceutical 9000-38-8
41
Citric acid Approved, Nutraceutical, Vet_approved Early Phase 1 77-92-9 311
42
N,N-dimethylarginine Experimental 30315-93-6 123831
43 calcium heparin
44 Anesthetics
45 Natriuretic Peptide, Brain
46 Anticoagulants
47 Tea
48 Citrate Early Phase 1
49 Phosphodiesterase 5 Inhibitors Early Phase 1
50 Sildenafil Citrate Early Phase 1 171599-83-0

Interventional clinical trials:

(show top 50) (show all 89)
# Name Status NCT ID Phase Drugs
1 Device Closure Versus Medical Therapy for Secondary Prevention in Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale : DEFENSE-PFO Unknown status NCT01550588 Phase 4 Standard medical treatment
2 Randomized Clinical Trial Comparing the Efficacy of Percutaneous Closure of Patent Foramen Ovale (PFO) With Medical Treatment in Patients With Cryptogenic Embolism Unknown status NCT00166257 Phase 4 Medical antitrhombotic treatment
3 Patent Foramen Ovale in Cryptogenic Stroke Study Completed NCT00697151 Phase 4 Warfarin;Aspirin
4 A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex® Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale Unknown status NCT00201461 Phase 2, Phase 3 Best medical therapy
5 A Prospective, Multi-Center, Double-Blinded, Placebo-Controlled Trial to Evaluate the Effectiveness of Patent Foramen Ovale Closure With the BioSTAR Septal Repair Implant to Reduce Refractory Migraine Headache With Aura. Unknown status NCT00283738 Phase 2, Phase 3
6 Closure of Patent Foramen Ovale or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence Completed NCT00562289 Phase 3 aspirin;Antivitamins K or rivaroxaban or dabigatran or apixaban
7 Medtronic Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF)/Permanent Study Completed NCT00431834 Phase 3
8 Medtronic Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF)/Persistent Study Completed NCT00506493 Phase 3
9 FDS-0004 Cardiox Shunt Detection Technology Study Terminated NCT01333761 Phase 3
10 A With-in Subject, Controlled Study to Determine the Sensitivity and Specificity of the Cardiox Flow Detection System for the Detection of Right-to-Left Cardiac Shunts Compared to Transesophageal Echocardiography and Transcranial Doppler Ultrasound Terminated NCT01773252 Phase 3
11 Precutaneous High Risk Patent Foramen Ovale to Treat Migraine Headaches:A Prospective,Multicenter,Randomized,Controlled Trial Unknown status NCT02777359 Phase 2
12 Percutaneous Closure of Patent Foramen Ovale In Migraine With Aura - A Randomized Prospective Study (Prima Trial) Terminated NCT00505570 Phase 2
13 PARADOX Trial: A Prospective, Double-Blind, Randomized Controlled Trial in Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli Withdrawn NCT02378623 Phase 2 Apixaban;Placebo
14 Occluder Size Determination in Transcatheter Closure of Ostium Secundum Atrial Septal Defect Based on Three-Dimensional Echocardiography Assessment Unknown status NCT02601768
15 PFO Closure for Obstructive Sleep Apnoea-1 Study Unknown status NCT02771561
16 Feasibility Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism Unknown status NCT00196027
17 Influence of Position on Detection of Patent Foramen Ovale by Simultaneous Transesophageal Echo and Transcranial Doppler Unknown status NCT02383836
18 Migraine Characteristics in Patients Undergoing PFO (Patent Foramen Ovale) Closure: Evaluation of a Specific Risk Profile Unknown status NCT03521193
19 Prospective Clinical Follow-up of Patients Presenting With Cryptogenic Stroke Treated With the Percutaneous Closure of a Patent Foramen Ovale Unknown status NCT01149447
20 Timing of Closure of Patent Foramen Ovale and Patent Ductus Arteriosus Following Birth Unknown status NCT01032785
21 InterSEPT: In-Tunnel SeptRx European PFO Trial: A Prospective, Multi-Center Study to Evaluate the Safety and Performance of the SeptRx IPO PFO Closure System Unknown status NCT01385670
22 Clinical Proteomic Research on the Brain Unknown status NCT00983723
23 Emergency/Compassionate Use PFO Occluder Approved for marketing NCT00584064
24 Prospective, Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects With Migraine and PFO Using the AMPLATZER PFO Occluder to Medical Management. Completed NCT00355056
25 Residual Shunt After Patent Foramen Ovale Device Closure in Patients With Cryptogenic Stroke: Serial Bubble Contrast Transesophageal Echocardiography Data Completed NCT03416426
26 GORE® Septal Occluder Clinical Study: A Study to Evaluate Safety and Efficacy in the Treatment of Transcatheter Closure of Ostium Secundum Atrial Septal Defects (ASDs) Completed NCT01711983
27 Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine Completed NCT02127294
28 Patent Foramen Ovale and the Risk of Postoperative Delirium Following Elective Hip and Knee Arthroplasty Surgeries Completed NCT02400892
29 Post Market Clinical Follow-up Study of IrisFITTM PFO (Patent Foramen Ovale) Completed NCT02882815
30 Nitrogen Bubble Detection After Simulated Dives in Divers With PFO and After PFO Closure Completed NCT01854281
31 Multi-center, Prospective, Post-market Study Completed NCT02621528
32 Patent Foramen Ovale Closure Reduce in SCUBA-divers Completed NCT03997084
33 Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP) Completed NCT01257880
34 Is There a Link Between Venous Thromboembolism and Stroke in Patient With Patent Foramen Ovale ? Research for Stroke in Hospitalized Patients With Pulmonary Embolism. Completed NCT01216423
35 Prospective Single Center Pilot Clinical Study to Evaluate the Safety and Effectiveness of an Intracardiac Septal Closure Device With Biodegradable Framework in Patients With Clinically Significant Atrial Septum Defect (ASD) or Patent Foramen Ovale (PFO) Completed NCT01960491
36 Impact Of Closure Of Patent Foramen Ovale On Apnoea-Hypopnoea-Index, Nocturnal Hypoxemia And Systemic Vascular Function In Patients With Obstructive Sleep Apnoea Completed NCT01780207
37 Patent Foramen Ovale in Children With Migraine Headaches Completed NCT00750594
38 Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of an Intracardiac Septal Closure Device in Patients With Atrial Septum Defect (ASD) and Patent Foramen Ovale (PFO) Completed NCT00207376
39 GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients With Patent Foramen Ovale (PFO) - The Gore REDUCE Clinical Study Completed NCT00738894 Antiplatelet Medical Therapy
40 Silent Cerebral Infarcts in Patients With Pulmonary Embolism and a Patent Foramen Ovale: a Prospective Diffusion-weighted Magnetic Resonance Imaging Study. Completed NCT00831259
41 Feasibility Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness Completed NCT00196040
42 Correlation of Right-left Shunt Detection in Cardioembolism Etiology in Stroke Patient. Pilot Study. Completed NCT02351076
43 The Effect on Endothelial Progenitor Cells (EPCs) by Successful Cardiac Occlusion Device Implantation Completed NCT02957201
44 Single-center Non-comparative, Prospective Interventional Clinical Investigation on the Procedural Success and Safety of the Nit-Occlud® PFO Closure Device and Its Application System. Completed NCT00968032
45 Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis Completed NCT03377465
46 A Randomized, Controlled,Multi-Centre Trial of the Efficacy and Safety of the Occlutech Septal Occluder(Figulla Flex II) Compared to the AGA Septal Occluder(Amplatzer ASO) for Transcatheter Closure of Secundum ASD in Patients Completed NCT04488120
47 GORE® HELEX® Septal Occluder Post-Approval Study Completed NCT00581308
48 European CURE-AF Study - Concomitant Utilization of Radiofrequency Energy for Atrial Fibrillation Completed NCT04645615
49 Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT) Completed NCT00465270
50 Cardiac Troponin T After Transcatheter Closure of the Interatrial Septum Completed NCT03099967

Search NIH Clinical Center for Patent Foramen Ovale

Cochrane evidence based reviews: foramen ovale, patent

Sources

Genetic Tests for Patent Foramen Ovale

About this section

Genetic tests related to Patent Foramen Ovale:

# Genetic test Affiliating Genes
1 Patent Foramen Ovale 29
Sources

Anatomical Context for Patent Foramen Ovale

About this section

MalaCards organs/tissues related to Patent Foramen Ovale:

40
Heart, Brain, Endothelial, Spinal Cord, Lung, Kidney, Breast
Sources

Publications for Patent Foramen Ovale

About this section

Articles related to Patent Foramen Ovale:

(show top 50) (show all 5131)
# Title Authors PMID Year
1
Mutations in the NKX2-5 gene in patients with stroke and patent foramen ovale. 61 54
19464101 2009
2
Cases from the aerospace medicine residents' teaching file. Transient ischemic attack in an aviator with patent foramen ovale and Factor V Leiden. 54 61
14692478 2003
3
Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. 54 61
12695749 2003
4
Factor V Leiden mutation and patent foramen ovale in ischemic stroke. 61 54
12522679 2002
5
A fluorescein angiographic study of branch retinal artery occlusion (BRAO) - the retrograde filling of occluded vessels. 61 54
10611053 1999
6
Emerging risk factors for stroke: patent foramen ovale, proximal aortic atherosclerosis, antiphospholipid antibodies, and activated protein C resistance. 61 54
17894989 1997
7
Previously Undiagnosed Patent Foramen Ovale as Cause of Hypotension and Hypoxemia in a Patient With Recent TandemHeart LVAD Insertion. 61
33246871 2021
8
Atrial Cardiopathy and Likely Pathogenic Patent Foramen Ovale in Embolic Stroke of Undetermined Source. 61
32877955 2021
9
Operative risks of the Ross procedure. 61
33451826 2021
10
Pulmonary Venous Aneurysm Coiling for Hemoptysis via Known Patent Foramen Ovale. 61
33485507 2021
11
Dual-center experiences with interventional closure of patent foramen ovale: A medium-term follow-up study comparing two patient groups aged under and over 60 years. 61
33595868 2021
12
Percutaneous Thromboembolectomy in a High-Risk Surgical Patient With Thrombus Straddling a Patent Foramen Ovale. 61
33582080 2021
13
Patent Foramen Ovale Closure among Patients with Hypercoagulable States Maintained on Antithrombotic Therapy. 61
33582661 2021
14
Catheter-directed therapies for pulmonary embolism: considerations for patients with patent foramen ovale. 61
32557222 2021
15
A Case of Paradoxical Coil Embolism through a Patent Foramen Ovale. 61
33223389 2021
16
Short- and long-term haemodynamic consequences of transcatheter closure of atrial septal defect and patent foramen ovale. 61
33594591 2021
17
Thrombus straddling a patent foramen ovale in a patient with pulmonary embolism related to essential thrombocythemia. 61
33386598 2021
18
Concomitant AngioVac thrombectomy and patent foramen ovale closure in a patient with a large right atrial thrombus and recent paradoxical embolic stroke. 61
33599209 2021
19
Synthesis of systematic reviews of percutaneous device closure of patent foramen ovale (PFO) for prevention of recurrent cryptogenic stroke: Redundant publications and methodological deficiencies. 61
33098809 2021
20
Patent foramen ovale presenting with platypnoea-orthodeoxia syndrome and stroke after multi-organ resection. 61
33542004 2021
21
Patent foramen ovale closure in the management of cryptogenic stroke: a review of current literature and guideline statements. 61
33460329 2021
22
Advances and Ongoing Controversies in Patent Foramen Ovale Closure and Cryptogenic Stroke. 61
33223089 2021
23
Impact of Patent Foramen Ovale Anatomic Features on Right-to-Left Shunt in Patients with Cryptogenic Stroke. 61
33541750 2021
24
Association of first trimester prescription opioid use with congenital malformations in the offspring: population based cohort study. 61
33568363 2021
25
Cardiac sources of cerebral embolism in people with migraine. 61
32979886 2021
26
Pooled Analysis of PFO Occluder Device Trials in Patients With PFO and Migraine. 61
33573735 2021
27
Association between Migraine and Cryptogenic Ischemic Stroke in Young Adults. 61
33078475 2021
28
Comment on 'Clopidogrel can be an effective complementary prophylactic for drug-refractory migraine with patent foramen ovale'. 61
33443050 2021
29
Patent foramen ovale closure for secondary prevention of cryptogenic stroke. 61
33605829 2021
30
Patients after persistent foramen ovale (PFO) closure: long-term benefits and risks. A contemporary approach to guide clinical decision making. 61
33599457 2021
31
Stroke During Hip Surgery. 61
33531447 2021
32
Primary Sternal Cleft Repair in First Week of Life. 61
33591229 2021
33
The Mechanism of Balloon Impact in Percutaneous Transluminal Coronary Angioplasty in Eccentric Coronary Artery Narrowings. 61
33548188 2021
34
Diagnosis of patent foramen ovale using maximum intensity T-projection imaging. 61
33394216 2021
35
Proper Sizing of Patent Foramen Ovale and Grading of Residual Right-to-Left Shunt. 61
33413856 2021
36
Suture-Mediated Percutaneous Patent Foramen Ovale Closure: A Call for Careful Imaging Assessment. 61
33413857 2021
37
Efficacy of Saline Contrast Transthoracic Echocardiography for Identifying High-Risk Patent Foramen Ovale. 61
32888759 2021
38
Long-term follow-up outcomes in a real-world study cohort after percutaneous patent foramen ovale closure. 61
33390571 2021
39
[Patent foramen ovale. An update for primary care]. 61
33509725 2021
40
Assessment of left ventricular filling pressure with Doppler velocities across the patent foramen ovale. 61
33438170 2021
41
Transcatheter closure of patent foramen ovale: Current evidence and future perspectives. 61
33144025 2021
42
Diverse manifestations of a sickle cell crisis. 61
33509861 2021
43
Efficacy of patent foramen ovale closure for treating migraine: a prospective follow-up study. 61
32928904 2021
44
Prevalence and grade of RLS in migraine: A prospective study of 251 migraineurs by synchronous test of c-TTE and c-TCD. 61
33530208 2021
45
European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions. 61
33507260 2021
46
European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions. 61
33506796 2021
47
Prenatal diagnosis of familial 22q11.2 deletion syndrome in a pregnancy with concomitant cardiac and urinary tract abnormalities in the fetus and the mother. 61
33494995 2021
48
Carotid Atherosclerosis and Patent Foramen Ovale in Embolic Stroke of Undetermined Source. 61
33137616 2021
49
Management of Patients With a Patent Foramen Ovale With History of Stroke or TIA. 61
33399834 2021
50
Congenital portosystemic shunt occlusion with an Amplatzer PFO occlusion device: a case report. 61
33427962 2021
Sources

Variations for Patent Foramen Ovale

About this section

ClinVar genetic disease variations for Patent Foramen Ovale:

6 (show all 12)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FLNC-AS1 NM_001458.5(FLNC):c.7562-15_7637delinsGAGG Indel Pathogenic 599235 rs1563005360 7:128497157-128497247 7:128857103-128857193
2 TBX5 NM_000192.3(TBX5):c.1221C>G (p.Tyr407Ter) SNV Pathogenic 495227 rs1555223259 12:114793673-114793673 12:114355868-114355868
3 NSD1 NM_022455.4(NSD1):c.3839G>A (p.Trp1280Ter) SNV Pathogenic 159315 rs587784105 5:176662864-176662864 5:177235863-177235863
4 PTPN11 NM_002834.5(PTPN11):c.184T>G (p.Tyr62Asp) SNV Pathogenic 13329 rs121918460 12:112888168-112888168 12:112450364-112450364
5 TAB2 NM_001292034.3(TAB2):c.1039C>T (p.Arg347Ter) SNV Likely pathogenic 373443 rs1057518422 6:149700090-149700090 6:149378954-149378954
6 FGF14 NM_004115.3(FGF14):c.486dup (p.Arg163fs) Duplication Likely pathogenic 598976 rs1566823361 13:102379082-102379083 13:101726732-101726733
7 AAR2 NM_001271874.2(AAR2):c.520G>A (p.Val174Met) SNV Likely pathogenic 242897 rs746800707 20:34828310-34828310 20:36240388-36240388
8 TBXAS1 GRCh37/hg19 7q34(chr7:139478979-139550968) copy number gain Uncertain significance 638674 7:139478979-139550968
9 GABRG3 GRCh37/hg19 15q12(chr15:27462869-27544157) copy number gain Uncertain significance 638675 15:27462869-27544157
10 PKD1 NM_001009944.3(PKD1):c.226C>T (p.His76Tyr) SNV Uncertain significance 523385 rs932577597 16:2169369-2169369 16:2119368-2119368
11 RNF213-AS1 NM_001256071.3(RNF213):c.11659A>G (p.Lys3887Glu) SNV Uncertain significance 523426 rs1555673862 17:78337499-78337499 17:80363699-80363699
12 TRPM4 NM_017636.4(TRPM4):c.1376G>A (p.Arg459His) SNV Likely benign 468927 rs142312281 19:49685947-49685947 19:49182690-49182690
Sources

Expression for Patent Foramen Ovale

About this section
Search GEO for disease gene expression data for Patent Foramen Ovale.
Sources

Pathways for Patent Foramen Ovale

About this section

Pathways related to Patent Foramen Ovale according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 12.88 SERPINC1 PTPN11 GATA6 GATA4 F5 F2
2
Cardiac conduction 65
Show member pathways
 12.45 TBX5 NKX2-5 MYH6 GATA4 FGF14
3
Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.52 TBX5 NKX2-5 GATA4
4
Cardiac Progenitor Differentiation 1
11.16 TBX5 TBX20 NKX2-5 MYH6 GATA4 ACTC1
5
Heart Development 1
10.76 TBX5 TBX20 PTPN11 NKX2-5 GATA6 GATA4
6
HOP Signaling 63
10.11 NKX2-5 GATA4 ACTC1
Sources

GO Terms for Patent Foramen Ovale

About this section

Cellular components related to Patent Foramen Ovale according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin GO:0000785 9.17 TBX5 TBX20 NSD1 NKX2-5 GATA6 GATA4

Biological processes related to Patent Foramen Ovale according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 10.17 TBX5 TBX20 NSD1 NKX2-5 GATA6 GATA4
2 positive regulation of transcription, DNA-templated GO:0045893 10 TBX5 TBX20 NSD1 NKX2-5 GATA6 GATA4
3 response to drug GO:0042493 9.92 MTHFR GATA6 GATA4 ACTC1
4 cellular protein metabolic process GO:0044267 9.88 SERPINC1 GATA6 F5 F2
5 heart development GO:0007507 9.88 TBX5 TAB2 PTPN11 NKX2-5 CITED2
6 blood coagulation GO:0007596 9.83 SERPINC1 GATA6 GATA4 F5 F2
7 male gonad development GO:0008584 9.82 GATA6 GATA4 CITED2
8 vasculogenesis GO:0001570 9.74 TBX20 NKX2-5 CITED2
9 hemostasis GO:0007599 9.73 SERPINC1 F5 F2
10 cardiac muscle contraction GO:0060048 9.72 NKX2-5 MYH6 ACTC1
11 positive regulation of cardiac muscle cell proliferation GO:0060045 9.71 TBX5 TBX20 GATA6
12 heart looping GO:0001947 9.71 TBX20 NKX2-5 GATA4 CITED2
13 ventricular septum development GO:0003281 9.7 TBX5 GATA4 CITED2
14 aortic valve morphogenesis GO:0003180 9.69 TBX20 NKX2-5 GATA4
15 outflow tract septum morphogenesis GO:0003148 9.67 TBX20 NKX2-5 GATA6
16 embryonic heart tube development GO:0035050 9.64 TBX20 NKX2-5
17 blood coagulation, intrinsic pathway GO:0007597 9.63 F2 APOH
18 positive regulation of blood coagulation GO:0030194 9.62 F2 APOH
19 cardiac right ventricle morphogenesis GO:0003215 9.61 TBX20 GATA4
20 cardiac muscle hypertrophy in response to stress GO:0014898 9.61 MYH6 GATA6
21 adult heart development GO:0007512 9.6 NKX2-5 MYH6
22 negative regulation of fibrinolysis GO:0051918 9.59 F2 APOH
23 intestinal epithelial cell differentiation GO:0060575 9.58 GATA6 GATA4
24 regulation of blood coagulation GO:0030193 9.54 SERPINC1 F2 APOH
25 cardiac muscle tissue morphogenesis GO:0055008 9.5 TBX20 NKX2-5 ACTC1
26 cardiac muscle cell differentiation GO:0055007 9.46 TBX5 NKX2-5 GATA6 GATA4
27 endocardial cushion development GO:0003197 9.43 TBX5 GATA4 CITED2
28 atrial septum morphogenesis GO:0060413 9.26 TBX5 TBX20 NKX2-5 GATA4
29 positive regulation of cardioblast differentiation GO:0051891 8.92 TBX5 NKX2-5 GATA6 GATA4

Molecular functions related to Patent Foramen Ovale according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 bacterial-type RNA polymerase transcriptional activator activity, sequence-specific DNA binding GO:0001216 8.96 NKX2-5 GATA4
2 heparin binding GO:0008201 8.92 SERPINC1 FGF14 F2 APOH
Sources

Sources for Patent Foramen Ovale

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....